Changes and clinical significance of serum fibroblast growth factor 21 and nuclear peroxisome proliferator-activated receptor γ levels in patients with coronary heart disease
LIN Puqing HONG Changjiang WU Shan HU Zhongzhi
Department of Cardiology, Clifford Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 511495, China
Abstract：Objective To investigate the changes and clinical significance of serum fibroblast growth factor 21 (FGF21) and nuclear peroxisome proliferator-activated receptor γ (PPARγ) levels in patients with coronary heart disease (CHD). Methods A total of 129 patients with CHD confirmed by coronary angiography during hospitalization in Clifford Hospital of Guangzhou University of Chinese Medicine (hereinafter referred to as “our hospital”) from March 2018 to March 2019 were selected as the observation group, and 80 person who came to our hospital for physical examination during the same period were selected as the control group. The observation group was divided into mild group (n = 45), moderate group (n = 55) and severe group (n = 29) according to the degree of coronary artery disease. The observation group was divided into single-vessel lesion group (n = 48), double-vessel lesion group (n = 44) and multi-vessel lesion group (n = 37) according to the number of coronary artery lesion branches. Serum FGF21 and PPARγ levels in each group were determined by enzyme-linked immunosorbent assay, and the relationship between FGF21 and PPARγ levels and Gensini score and lesion count was analyzed. Results Serum FGF21 and PPARγ levels of patients in the observation group were significantly higher than those in the control group, and the differences were statistically significant (all P ＜ 0.05). Among the CHD patients with different degrees of coronary artery disease, the FGF21 and PPARγ levels in the moderate group were higher than those in the mild group, while those in the severe group were higher than those in the moderate group and the mild group, with statistically significant differences (all P ＜ 0.05). Among the CHD patients with varying degrees of coronary artery lesions, the FGF21 and PPARγ levels in the double-vessel lesion group were higher than those in the single-vessel lesion group, while those in the multiple-vessel lesion group were higher than those in the double-vessel lesion group and the single-vessel lesion group, with statistically significant differences (all P ＜ 0.05). Spearman correlation analysis found that FGF21 and PPARγ levels in CHD patients were positively correlated with lesion count and Gensini score (r ＞ 0，P ＜ 0.05), and FGF21 levels were positively correlated with PPARγ levels (r ＞ 0，P ＜ 0.05). Conclusion The levels of FGF21 and PPARγ are increased in CHD patients, and the levels of FGF21 and PPARγ are closely related to the stenosis degree and accumulation of coronary artery lesions.
[1] 陈婷，胡明露，赵稼萤.通痹汤对冠心病心绞痛患者内皮功能及血液流变学的影响[J].国际中医中药杂志，2019， 41（2）：120-124.
[2] 杨保军，张丽平，殷洪山，等.冠心病与糖代谢异常关系临床调查分析[J].河北医科大学学报，2017，38（7）：819-821.
[3] Bhupathiraju SN，Guasch-Ferré M，Gadgil MD，et al. Dietary Patterns among Asian Indians Living in the United States Have Distinct Metabolomic Profiles That Are Associated with Cardiometabolic Risk [J]. J Nutr，2018，148（7）：1150-1159.
[4] Kovari H，Rauch A，Kouyos R，et al. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study [J]. Clin Infect Dis，2017，64（4）：490-497.
[5] Lee CH，Woo YC，Chow WS，et al. Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus [J]. J Am Heart Assoc，2017，6（6）：e005344.
[6] Morris A. Obesity：Pharmacological actions of FGF19 and FGF21 revealed [J]. Nat Rev Endocrinol，2017，13（12）：690.
[7] González-Castro TB，Tovilla-Zárate CA，Juárez-Rojop IE，et al. PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease [J]. Biomark Med，2018，12（3）：287-297.
[8] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管病预防指南[J].柳州医学，2012，5（4）：263-279.
[9] 祖凌云，葛洪霞，高炜.SYNTAX积分和Gensini评分对急性ST段抬高心肌梗死患者远期心血管事件的预测价值[J].中国介入心脏病学杂志，2014，22（12）：755-760.
[10] 吴多宏，吴淼，李明，等.血浆AT-Ⅲ、CD93水平与冠心病患者非高密度脂蛋白水平和Gensini评分的关系研究[J].疑难病杂志，2018，17（12）：1301-1305.
[11] 吴少平.血清胆红素水平与冠状动脉粥样硬化性心脏病的相关性研究[J].中国临床新医学，2018，11（1）：54-57.
[12] 吴和弟，许丽娃，吉家钗，等.2型糖尿病合并冠心病患者血清PCT、hs-CRP及血脂水平与冠状动脉病变的关系分析[J].疑难病杂志，2018，17（10）：1094-1098.
[13] Sun H，Zhang J，Zheng Y，et al. Expressions and clinical significance of factors related to acute coronary syndrome [J]. J Biol Regul Homeost Agents，2018，32（2）：299-305.
[14] Kharitonenkov A，Shiyanova TL，Koester A，et al. FGF-21 as a novel metabolic regulator [J]. J Clin Invest，2005， 115（6）：1627-1635.
[15] Qi M，Xin S. FGF signaling contributes to atherosclerosis by enhancing the inflammatory response in vascular smooth muscle cells [J]. Mol Med Rep，2019，20（1）：162-170.
[16] Gómez-Sámano M?魣，Grajales-Gómez M，Zuarth-Vázquez JM，et al. Fibroblast growth factor 21 and its novel association with oxidative stress [J]. Redox Biol，2017，11：335-341.
[17] Lin Z，Wu Z，Yin X，et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile [J]. PLoS One，2010，29，5（12）：e15534.
[18] Han L，Shen WJ，Bittner S，et al. PPARs：regulators of metabolism and as therapeutic targets in cardiovascular disease. Part Ⅱ：PPAR-β/δ and PPAR-γ [J]. Future Cardiol，2017，13（3）：279-296.
[19] Khosravi F，Kharazmi F，Kamran M，et al. The role of PPAR-γ and NFKB genes expression in muscle to improve hyperglycemia in STZ-induced diabetic rat following magnesium sulfate administration [J]. Int J Physiol Pathophysiol Pharmacol，2018，10（3）：124-131.
[20] Li T，Wang W，Li YX，et al. Pseudolaric acid B attenuates atherosclerosis progression and inflammation by suppressing PPARγ-mediated NF-κB activation [J]. Int Immunopharmacol，2018，59：76-85.
[21] Dutchak PA，Katafuchi T，Bookout AL，et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones [J]. Cell，2012， 148（3）：556-567.
2020, Vol. 17 
京公网安备 11010502046598号